title: High-dose aspirin consumption contributes to decreased risk for pancreatic cancer in a systematic review and meta-analysis.
abstract: OBJECTIVE
  The aim of this study was to analyze the association between aspirin intake and its effect for chemoprevention of pancreatic cancer incidence by using a meta-analysis method.
  
  
  METHODS
  The databases of MEDLINE, EMBASE, and Wangfang (Chinese database) were retrieved to identify eligible studies. Odds ratio (OR) and 95% confidence interval (CI) were calculated using a random-effects model.
  
  
  RESULTS
  A total of 10 studies (4 case-control studies, 5 prospective cohort studies, and 1 randomized controlled trial) with 7,252 cases of pancreatic cancer and more than 120,0000 healthy control subjects were enrolled in the studies. Pooled analyses showed that high-dose aspirin intake was marginally associated with decreased risk for pancreatic cancer for overall analysis (OR, 0.88; 95% CI, 0.76-1.01) as well as for both cohort and case-control studies (OR, 0.70; 95% CI, 0.54-1.16, for the cohort studies; OR, 0.82; 95% CI, 0.62-1.02, for the case-control studies), without between-study heterogeneity. Stratified analysis for Americans showed a similar result (OR, 0.82; 95% CI, 0.65-1.02). In contrast, our study inferred that low-dose aspirin intake was not associated with risk for pancreatic cancer for the total and subgroup analyses.
  
  
  CONCLUSIONS
  In summary, our study indicated that high-dose aspirin, rather than low-dose aspirin, might be associated with decreased risk for pancreatic cancer, especially for Americans.
authors.affiliation: From the *Department of General Surgery, Wendeng Central Hospital, Wei Hai City; †Department of General Surgery, Linyi People's Hospital, Lin Yi City, Shan Dong Province; ‡Department of Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou; and §Department of Gynaecology and Obstetrics, the First Affiliated Hospital of Xinxiang Medical College, Xinxiang, China.
authors.forename: Xi-Jun
authors.initials: XJ
authors.lastname: Cui
authors.forename: Qiang
authors.initials: Q
authors.lastname: He
authors.forename: Jian-Min
authors.initials: JM
authors.lastname: Zhang
authors.forename: Hui-Jie
authors.initials: HJ
authors.lastname: Fan
authors.forename: Zheng-Fang
authors.initials: ZF
authors.lastname: Wen
authors.forename: Yan-Ru
authors.initials: YR
authors.lastname: Qin
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000627:therapeutic use; D001241:Aspirin / Q000008:administration & dosage / Q000627:therapeutic use*; D016022:Case-Control Studies; D004305:Dose-Response Relationship, Drug; D006801:Humans; D010190:Pancreatic Neoplasms / Q000517:prevention & control*; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D001241:Aspirin